6 Cash-Heavy Biotech Stocks With Analyst Endorsements

Some investors consider investing in biotechnology to be too risky. But focusing on biotechs that have ample cash reserves is one way to mitigate that exposure. Having a high level of liquidity allows a company to continue research and development, make strategic acquisitions, and expand to new territories, not to mention withstand market upheavals. Today, the biotechnology stocks we chose to evaluate all have strong cash reserves and recent "Buy" ratings from industry analysts, indicating that they have much more than cash reserves going for them. Use our findings as a starting point for your own analysis.The current ratio is a liquidity ratio used to determine a company's financial health. The metric illustrates how easily a firm can pay back its short obligations all at once through current assets. A company that has a current ratio of one or less is generally a liquidity red flag. Now, this doesn't
... Read the rest at SeekingAlpha.com